Archive: November 2021

The Evolving Use of CAR T-Cell Therapy in Follicular Lymphoma

H&O  What clinical trial data led to the approval of chimeric antigen receptor (CAR) T-cell therapy in follicular lymphoma? LN  In March 2021, the US Food […]

The Use of ADAMTS13 Assays in Thrombotic Microangiopathies

H&O  What are thrombotic microangiopathies (TMAs), and how common are they? SC  TMAs are clinical syndromes in which blood clots occur in the smallest blood vessels […]

The Role of AR-V7 Testing in the Management of Metastatic CRPC

H&O  What is the rationale behind detection of the androgen receptor splice variant 7 (AR-V7) protein in men with prostate cancer?  AA  Prostate cancer is a […]

Total Neoadjuvant Therapy Approach in Rectal Adenocarcinoma

Abstract: The treatment of locally advanced rectal cancer has improved over the years owing to advancements in surgical techniques and chemoradiation, developing into a multidisciplinary approach […]

New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer

H&O  What data led the US Food and Drug Administration (FDA) to approve sacituzumab govitecan-hziy? AB  The antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy, Gilead) targets the human […]

DA-R-EPOCH vs R-CHOP in DLBCL: How Do We Choose?

Abstract: The emerging molecular and prognostic characterization of diffuse large B-cell lymphoma (DLBCL) has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in […]

To Boost or Not to Boost?

To boost or not to boost, that is the question—or rather, one of many questions regarding COVID-19 vaccination in the United States. Do we mandate vaccination […]

November 2021

How to Choose Second-Line Treatment for Hepatocellular Carcinoma

H&O  What are the current options for first-line medical treatment of hepatocellular carcinoma? CF  Recently, there has been a significant progression in the options that are […]

Back to Archive